SERES THERAPEUTICS, INC. (MCRB)

SERES THERAPEUTICS, INC. (MCRB) scores 49 out of 100 on boothcheck's 11-model valuation framework. Verdict: Poor The estimated fair value is 4.04, representing a 55% premium to fair value. Quantitative score: 45/100. Qualitative score: 80/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full MCRB analysis on boothcheck